jeudi 22 juin 2017

Onco Actu du 22 juin 2017

2.5 Etiologie - Gènes

Seven new DNA regions linked to kidney cancer risk [Institute of Cancer Research]

Genes that affect diseases and other traits may be scattered across genome [Stanford Medicine]

Thinking About Genetics and Disease [In the Pipeline]

5. Traitements

New Antibody Uses One-Two Punch to Potentially Treat Blood Cancers [ASH]

5.12 Immunothérapies

First-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung Cancer Patients [OSU]

5.12.5 Immunothérapies - Pharma

Cash-strapped ImmunoCellular halts brain cancer vaccine trial, eyes 'strategic alternatives' [FierceBiotech]

Running out of cash and cited on fraud charges, ImmunoCellular retreats on PhIII and cries for help [EndPoints]

5.2 Pharma

Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego [Lilly]

5.2.2 Pharma - Fusions & Acquisitions

Biopharma Outsourcing Is Going Through Deal Bonanza in U.S. [Bloomberg]

5.2.3 Pharma - économie

Repare Nabs $68M To Find Synthetic Lethal Cancer Targets Beyond PARP [Xconomy]

Top 20 blockbuster drugs in the late-stage pipeline — EvaluatePharma [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

Gottlieb’s FDA to rethink targeted therapy regulation to speed development, drive down healthcare costs [FierceBiotech]

A Meeting to Discuss FDA’s Continuing Conundrum: Innovation vs. Access [FDA Law Blog]

Landmark FDA approval bolsters personalized medicine [STAT]

FDA Working to Lift Barriers to Generic Drug Competition [FDA Voice]

U.S. FDA moves to prevent Pharma from 'gaming' generic drug system [Reuters]

5.9.3 EHA

Amgen To Present New Data At 22nd Congress of the European Hematology Association [Amgen]

6. Lutte contre les cancers

8 new challenges between us and beating cancer [Cancer Research UK]

First NHS proton beam machine arrives at Christie hospital [BBC News]

6.1 Observation

Air pollution tied to survival odds for liver cancer patients [Reuters]

6.4 Médico-éco

Cheshire cancer patients 'could die sooner' if NHS cuts are forced through [The Guardian]